[c09aa8]: / clusters / ordered9kclusters / clust_56.txt

Download this file

15 lines (14 with data), 2.1 kB

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
Drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen
As there is potential for hepatic toxicity with nivolumab or nivolumab non-drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen
As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution.
As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen.
Drugs with a predisposition to hepatoxicity should be used with caution
Drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen
As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen
Drugs with predisposition to hepatotoxicity should be used with caution in patients treated with nivolumab-containing regimen
Drugs with a predisposition to hepatotoxicity should be used with caution in patients treated with nivolumab-containing regimen
As there is potential for hepatic toxicity with nivolumab, drugs with a predisposition to hepatoxicity should be used with caution in subjects treated with nivolumab-containing regimen.
As there is potential for hepatic toxicity with nivolumab, drugs with a predisposition to hepatotoxicity should be used with caution in patients treated with nivolumab-containing regimen
Drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen
Drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen
Requires therapy with agents that have a predisposition for hepatoxicity